Kyntra Bio Inc Revenue Growth Rates (KYNB), Current and Historic Growth - CSIMarket
CSIMarket
 


Kyntra Bio Inc   (NASDAQ: KYNB)
 

KYNB's Revenue Growth by Quarter and Year

Kyntra Bio Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KYNB/growth
https://api.csimarket.com/api/v1/companies/KYNB/fundamentals
https://api.csimarket.com/api/v1/companies/KYNB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
KYNB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.76
2nd Quarter June -1.47
1st Quarter March 3.74
FY 4.03

KYNBs Annual Revenue
Kyntra Bio Inc 's Revenue in the fiscal year 2025 $ 6.44 millions
Kyntra Bio Inc 's Revenue in the fiscal year 2024 $ 29.62 millions
Kyntra Bio Inc 's Revenue in the fiscal year 2023 $ 147.75 millions
Kyntra Bio Inc 's Revenue in the fiscal year 2022 $ 140.73 millions
Kyntra Bio Inc 's Revenue in the fiscal year 2021 $ 235.31 millions




KYNB Revenue third quarter 2026 Y/Y Growth Comment
Kyntra Bio Inc achieved in the third quarter 2026, above Company average Revenue rise of 63.15% year on year, to $ 1.76 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 162 other companies have achieved higher Revenue growth. While Kyntra Bio Inc ' s Revenue jump of 63.15% ranks overall at the positon no. 3627 in the third quarter 2026.




KYNB Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 63.15 %
2nd Quarter June -
1st Quarter March 36.5 %
FY   -

Financial Statements
Kyntra Bio Inc 's third quarter 2026 Revenue $ 1.76 millions KYNB's Income Statement
Kyntra Bio Inc 's third quarter 2025 Revenue $ 1.08 millions Quarterly KYNB's Income Statement


KYNB Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 192.19 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #163
Healthcare Sector #496
Overall #3627

Revenue Y/Y Growth Statistics
High Average Low
142.01 % 0.43 % -95.87 %
(Jun 30 2019)   (Dec 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #163
Healthcare Sector #496
Overall #3627
Revenue Y/Y Growth Statistics
High Average Low
142.01 % 0.43 % -95.87 %
(Jun 30 2019)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Kyntra Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYNB's III. Quarter Q/Q Revenue Comment
Improvement III. Quarter 2026where Kyntra Bio Inc published Revenue of $ 1.76 millions should is starting point of positive performance.Kyntra Bio Inc announced in the III. Quarter 2026 Revenue of $ 1.76 millions compare to recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Kyntra Bio Inc achieved highest sequential Revenue growth. While Kyntra Bio Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYNB's III. Quarter Q/Q Revenue Comment
Improvement III. Quarter 2026where Kyntra Bio Inc published Revenue of $ 1.76 millions should is starting point of positive performance.Kyntra Bio Inc announced in the III. Quarter 2026 Revenue of $ 1.76 millions compare to recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Kyntra Bio Inc achieved highest sequential Revenue growth. While Kyntra Bio Inc 's Revenue growth quarter on quarter, overall rank is .


Kyntra Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.62
Y / Y Revenue Growth (TTM) -91.38 %
Year on Year Revenue Growth Overall Ranking # 3512
Seqeuential Revenue Change (TTM) -37.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 3473


Cumulative Revenue growth Comment
Kyntra Bio Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Kyntra Bio Inc 's annual Revenue drop would be -91.38% year on year to $5 millions.

In the Healthcare sector 481 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3512.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 158
Healthcare Sector # 482
Overall # 3512

Revenue TTM Y/Y Growth Statistics
High Average Low
142.01 %
2.72 %
-95.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 158
Sector # 473
S&P 500 # 3473
Cumulative Revenue growth Comment
Kyntra Bio Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Kyntra Bio Inc 's annual Revenue drop would be -91.38% year on year to $5 millions.

In the Healthcare sector 481 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3512.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 158
Healthcare Sector # 482
Overall # 3512

Revenue TTM Y/Y Growth Statistics
High Average Low
142.01 %
2.72 %
-95.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 158
Sector # 473
S&P 500 # 3473




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KYNB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Kyntra Bio Inc 63.75%$ 63.755 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions


About Kyntra Bio Inc Revenue Growth Rates (KYNB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Kyntra Bio Inc (CIK 921299).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-463519
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Kyntra Bio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.